59 results about "Complete remission" patented technology

Monoclonal gammopathy of undetermined significance can progress to multiple myeloma. Applying significance analysis of microarrays, 52 genes, involved in important pathways related to cancer, were differentially expressed between plasma cells from healthy subjects and patients with stringently defined monoclonal gammopathy of undetermined significance / smoldering multiple myeloma and symptomatic multiple myeloma. Unsupervised hierarchical clustering of 351 multiple myeloma and 44 cases of monoclonal gammopathy of undetermined significance and 16 cases of multiple myeloma with a monoclonal gammopathy of undetermined significance history, created two major cluster branches, one containing 82% of the monoclonal gammopathy of undetermined significance cases and 28% of the multiple myeloma, termed monoclonal gammopathy of undetermined significance-like multiple myeloma. Using the same clustering approach on an independent cohort of 213 cases of multiple myeloma revealed 27% with monoclonal gammopathy of undetermined significance-like multiple myeloma which, despite a lower incidence of complete remission, was associated with low-risk clinical and molecular features and superior survival. The monoclonal gammopathy of undetermined significance-like multiple myeloma signature was also seen in patients surviving more than 10 years after autotransplant.

The invention relates to specific chimeric antigen receptor T cells targeting CD19, and a preparation method and clinical application thereof. The present invention constructs a specific chimeric antigen receptor targeting CD19 and immune response cells modified by the chimeric antigen receptor based on a targeted human CD19 single-chain antibody sequence. The novel modified immune response cells can effectively target and attack a plurality of tumor cells, especially tumor cells with positive CD19 expressiion, and can be used to prepare a preparation for the treatment of tumors. The method for preparing the modified immune response cells targeting CD19 is simple, and the obtained modified immune response cells targeting CD19 have a high killing rate on tumor cells. Clinical verification shows that: after a million-grade low-dose back transfusion, patients with recurrent and refractory advanced CD19-positive lymphoma get a significant clinical symptom relief after two weeks of treatment, almost complete relief curative effect is obtained on the 77th day, and no fever caused by cytokine release syndrome and any neurotoxic side effect occur.

The invention relates to a chimeric antigen receptor, nucleic acid encoding the same, cells expressing the chimeric antigen receptor, and application of the chimeric antigen receptor in preparing drugs for treating tumors. The chimeric antigen receptor comprises at least one extracellular structural domain, an optional membrane spanning structural domain and at least one intracellular co-stimulation signal transduction structural domain, wherein the extracellular structural domains involve CD19 antigen recognition binding structural domains. The chimeric antigen receptor has a longer in-vivo survival period after being subjected to humanized transformation, and the complete remission period of a patient can also be prolonged accordingly.

Methods for identifying patients with molecular or complete remission of colorectal cancer following therapy a fluorocytidine derivative and a COX-2 enzyme inhibitor by quantifying CD 133 expression levels. Methods for detecting cancer stem cells by quantifying serum CD 133 RNA levels are also provided.

The invention discloses a soap pod saponin extract, a preparation method thereof and an application for curing lung cancer, liver cancer, stomach cancer, colorectal cancer and leukemia. The soap pod saponin extract uses fructus gleditsiae or fructus gleditsiae sinensis as the raw material and is prepared by the extraction of ethanol, and the separation and the purification of macroporous resin, and the content of total saponin of the extract is more than 60 percent. The saponin extract mainly comprises various pentacyclic triterpene saponin compounds, has obvious lethal effect on the clone of the leukemia progranulocyte HL-60 and the stomach cancer transferring lymphocyte SGC7901 of people, and has remarkably inhibited effect on the tumor of mice S180 and mice having the liver cancer. When capsules prepared by the extract are used for curing 40 examples having liver cancer, lung cancer, stomach cancer and colorectal cancer, the partial remission rate is 45 percent, and the partial remission and stabilization rate is 72.5 percent. When the capsules are used for curing 30 patients who have leukemia, the complete remission rate is 66.7 percent, and the total remission rate is 90 percent which is better than that of a single chemo-treatment group. The extract can obviously lighten the toxic side effect caused by the chemo-treatment.

The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain / inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and / or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.

The present invention provides a sinus relief composition and a method of producing the composition comprising oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients, vegetable glycerin, purified water, eucalyptol, rosemary extract, ascorbic acid, and sea salt for fully relieving and preventing chronic and occasional sinus, allergy, and headache symptoms, including pain, dryness, inflammation, congestion, and coughing.

Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments of the invention are useful for treating skin afflictions including common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis and rosacea.

There is provided means for increasing complete remission rates and shortening a period to complete remission and for achieving a synergistic effect with immunotherapy that is directed at bringing about enhanced effects from molecule-targeting therapeutic drugs. More specifically, an object is to achieve a synergistic effect by combining use of a novel immunotherapy for cancer that focuses on CTL activity, NKT activity, NK activity and −VEGF and the like, and molecule-targeting therapeutic drugs, particularly tyrosine kinase inhibitors. The present invention was accomplished based on the finding that combined use of a tyrosine kinase inhibitor and an IL-12 inducer achieves a superior synergistic effect in cancer therapy.

A topical medicine for relaxing the pain and / or inflammation caused by herpes virus (HSV or VZV) contains diclofenac (or NSAID). The etodolac, ketoralac, ketoprofen, bromfenac, etc can be also contained. Its advantages are high curative effect and short course of treatment (7 days).

The invention relates to the field of leukemia medicine, in particular to a medicine composition for treating leukemia and a preparation method thereof. The medicine composition is mainly prepared from, by weight, 2-8% of realgar, 25-42% of indigo naturalis, 50-60% of salviae miltiorrhizae and 6-10% of radix pseudostellariae. The preparation method of salviae miltiorrhizae is improved, the amount of water added to salviae miltiorrhizae is decreased, the number of decoction times is decreased, the decoction time is shortened, it is ensured that effective components of salviae miltiorrhizae are not damaged, the effective component tanshinone IIA for controlling indexes is detected through a high performance liquid chromatograph, the extraction rate reaches 75%, activity of all effective components is well kept, and the extraction rate is kept at a high level. When the medicine composite improved according to the prior art is used for treating leukemia clinically, the complete remission rate reaches 92.9%, the treatment effect is obviously increased and improved, and toxic and side effects are greatly reduced.

The invention discloses a pure traditional Chinese medicine preparation for treating multiple myeloma. The multiple myeloma belongs to categories of lumbago, rheumatism involving bones, consumptive diseases and the like in the traditional Chinese medicine. The clinical manifestations of the multiple myeloma are osteodynia, anemia, pyrexia and the like. The pathogenesis of the multiple myeloma is that disorder of yin and yang as well as qi and blood and viscera loss cause qi-blood disharmony, phlegm-blood stasis and implication of heat toxicity. The traditional Chinese medicine for treating the multiple myeloma comprises albumin-removing and myeloablative decoction prepared from carapax amydae, callicarpa bodinieri, radix astragali, radix psuedostellariae, angelica sinensis and the like, myeloablative and myeloma-removing powder prepared from centipede, venenum bufonis, scaly anteater, tortoise plastron, periostracum cicadae and the like, and anti-albumin capsules prepared from agkistrodon, mole cricket, ground beetle, mylabris and the like. Through clinical trials by our hospital, the medicine has a complete remission rate of 81.3% and small toxic and side effects, the treatment cost is low in, and the medicine deserves clinical popularization and application.

The present invention belongs to the field of Chinese medicine technology, and especially a kind of compound Chinese medicine preparation for treating headache and / or dysmenorrhea caused by stagnation of Qi and blood stasis and its preparation process. The compound Chinese medicine preparation is developed based on the Chinese medicine theory of promoting blood circulation and dispersing blood clots to stop pain, and is prepared with corydalis tuber, trogopterus dung, frankincense, myrrh and evodia fruit and through grinding or extracting, adding medicinal supplementary material and further processing to prepare granule, tablet, capsule, etc. Clinical application shows that the compound Chinese medicine preparation has high pain relieving effect and no adverse reaction. The compound Chinese medicine preparation may be also used for treating pain caused by other causes.

Provided herein are treatments of autoimmune conditions by the topical, oral or intravenous use of an active agent, including acetylcholinesterase inhibitors, in an amount effective to reduce or eliminate mites. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the autoimmune afflictions than previously described methods. Methods are useful for treating autoimmune diseases.

The invention belongs to the technical field of Chinese medicines, and relates to a Chinese medicinal preparation for treating a coronary heart disease. The Chinese medicinal preparation is prepared from the following bulk pharmaceuticals in parts by weight: 15-20g of ginseng, 20-30g of red-rooted salvia root, 5-10g of cinnabar, 5-10g of white paeony root, 15-20g of szechuan lovage rhizome, 20-30g of astragalus, 10-15g of leech, 5-10g of longstamen onion bulb, 5-10g of tall gastrodia tuber, 5-10g of frankincense, 2-5g of sandalwood, 10-15g of dalbergia wood, 1-2g of clove, 1-3g of costus root and 5-10g of salted prepared common monkshood daughter root. The bulk pharmaceuticals are smashed and sieved with a 180-mesh sieve into powder, and the powder is filled into capsules. The Chinese medicinal preparation has good curative effects on symptoms such as chest pain, short breath, dreaminess, light-headedness, general debility and the like caused by symptoms such as angina caused by the coronary heart disease. As proved by the clinical treatment effect of Chinese-medicine classifying treatment based on syndrome differentiation on thousands of patients suffering from heart diseases of different types, the symptoms of 80 percent of patients are relieved completely, the apparent rate is up to 65 percent, and the total effective rate is over 98 percent.

The invention discloses a pain-alleviating traditional Chinese medicine composition and application thereof. The pain-alleviating traditional Chinese medicine composition is prepared from the following medicinal materials in percentages by weight: 10 to 30 percent of garden balsam, 10 to 30 percent of spreading hedyotis, 5 to 20 percent of ginseng, 5 to 20 percent of radix astragali and 1 to 5 percent of pearl powder. By an experiment, the applicant discovers that the toxic and side effects of the traditional Chinese medicine composition described by the invention are little, the total effective rate of the traditional Chinese medicine composition in alleviating cancerous pain is 100 percent, the complete remission rate in controlling cancerous pleural effusion, pericardial effusion and ascites reaches 94 percent, and the effective rate reaches 98 percent; the traditional Chinese medicine composition also has a remarkable effect in controlling the growth of tumors; the traditional Chinese medicine composition has a strong inhibition effect on human erythroleukemia cells.

The invention provides traditional Chinese medicinal enteric-coated tablets for treating proctitis, colitis and irritable bowel syndrome, as well as a preparation method and application thereof. Active components for preparing the traditional Chinese medicinal enteric-coated tablets comprise the following traditional Chinese medicinal raw materials in parts by weight: 200-800 parts of smoked plum, 50-400 parts of golden thread, 50-400 parts of dried ginger, 50-400 parts of costustoot, 50-300 parts of pericarpium papaveris, and 50-300 parts of rhizoma corydalis. Clinical researches on ulcerative colitis prove that, the traditional Chinese medicinal enteric-coated tablets have a cure rate of 59.1 percent in a treatment group, and a total effective rate of 98.1 percent. Clinical researches on irritable bowel syndrome prove that traditional Chinese medicinal enteric-coated tablets have a complete remission rate of 67.8 percent in the treatment group, and a total effective rate of 95.2 percent. In clinical researches on proctitis, the traditional Chinese medicinal enteric-coated tablets are used for treating 36 cases, wherein 32 cases are cured, 3 cases are improved, 1 case is invalid, and the total effective rate is 88.8 percent. The researches prove that the enteric-coated tablets have remarkable advantages and improvement in treatment after the preparation and dose forms are improved, and are advantageous to clinical application. The traditional Chinese medicinal enteric-coated tablets are easily available in raw materials, simple in method and pollution free, is suitable for industrial production, and has higher application value.

Provided herein are treatments of autoimmune conditions by the topical, oral or intravenous use of an active agent, specifically including chloroquine and / or hydroxychloroquine, in an amount effective to reduce or eliminate mites. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the autoimmune afflictions than previously described methods. Methods are useful for treating autoimmune diseases.

The invention discloses an application of a TCR[gamma][delta]T cell subfamilies in preparing a kit for predicting a curative effect and prognosis evaluation of AML (acute myeloid leukemia). The invention is based on the technical scheme which is proposed when the inventor of the invention discovers a relationship between the clonal proliferation situation of peripheral blood [gamma][delta]T cell TRDV1-RTDV8 subfamilies of a patient with the AML and the curative effect and the prognosis of the patient with the AML for the first time. The clonally-proliferated TRDV4 and TRDV8 subfamilies, as protective factors, are related to the complete remission of the patient with the AML, and the clonally-proliferated TRDV5 and the TRDV6 subfamilies are related to the recurrence of the patient with the AML. The pedigree analysis and clonal proliferation situation of the TCR[gamma][delta]T cell subfamilies have a broad prospect in the aspects of predicting the clinical curative effect and prognosis evaluation of the patient with the AML, and more fundamental research data can be provided for the individualized treatment of the AML.

The invention provides a traditional Chinese medicine for treating qi and blood stasis stagnation type pancreatic cancer and a preparation method thereof. All raw medicinal materials of the traditional Chinese medicine comprise bambusa pervariabilis, rhizoma arundinis, droughtdysentery holarrhena bark, lygodium japonicum, bulbophyllum inconspicuum maxim, scytosiphon lomentarius, impure mirabilite, tricuspid cudrania bark, herb of wormseed mustard, root of angled bittersweet, camphor root, asiatic bilberry, herb of Indian pentanema, euonymus sanguineus, three-leaved pronephrium herb, all-grass of sida cordifolia and sanvitalia procumbens. The traditional Chinese medicine provided by the invention is matched with chemoradiotherapy for use, so that the therapeutic effect of chemotherapy is improved, side effects of the chemotherapy are reduced, lumps can be reduced in short term, the diffusion and transfer of cancer cells are effectively controlled, the body immune function can be enhanced and further the growth of the cancer cells is suppressed, and no side effects are generated; the aims of enhancing the body immunity while treating and resisting the cancer, relieving pains of patients, stabilizing disease conditions, prolonging the survival period and increasing the proportion of patients realizing clinical complete remission are achieved.

The invention relates to a traditional Chinese medicine composition for treating B cell lymphoma. The traditional Chinese medicine composition is prepared from such raw materials as baikal skullcap root, selfheal, turmeric and astragalus membranaceus. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the curative effect of treating incipient moderately high risk DLBCL by use of an R-CHOP scheme is enhanced and complete relief can be achieved more early, the CR rate of a patient having poor overall functional status KPS is increased, the toxic and side reaction, in particular the non-hematological toxicity, of chemotherapy is relieved, a protection effect can be achieved on CD3+CD4+T cells and CD4+CD28+ cells, and the CD4+ / CD8+ cell ratio can be increased.

The invention discloses an application of an ER and Ki-67 expression ratio in endometrial tissues in fertility function retention treatment prognosis of endometrial cancer (EC) and atypical endometrial hyperplasia (AH). According to the invention, 53 EC patients and 68 AH patients orally take MPA or MA, then gonadotropin is combined to release a hormone agonist and / or a levoynorethindrone intrauterine sustained release system, the patients are divided into a recurrence group and a non-recurrence group according to whether recurrence occurs after complete remission, then ER, PR, P16, P53, PTEN, Ki-67 and the like are subjected to immunohistochemical analysis, and statistical analysis is carried out. Results show that the expression rate of the Ki-67 is of great significance in predicting recurrence after the EC and AH retention fertility function treatment, and the optimal critical value (3.55) of ER / Ki-67 can predict recurrence after the EC and AH retention fertility function treatment better than that of a single immunohistochemical marker. The method has an important application value.

The present invention provides a method of predicting and determining a therapeutic effect (especially whether complete remission is reached) or the level of improvement prior to administration of a biological formulation such as an anti-IL-6 agent or an anti-TNF-α agent, which is simple and cost-effective, and accurate. Sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, MIP-1α and the like can be utilized as a specific marker used in the method. Since a therapeutic effect (level of improvement in a symptom or possibility of remission) on a rheumatoid arthritis patient can be determined prior to the administration of a biological formulation using such a specific marker, rheumatoid arthritis therapy is possible at a precision that could not be achieved conventionally.

The invention belongs to the technical field of good processing, and particularly relates to a health care tea with hair generating and kidney benefiting efficacies. The health care tea is prepared from the following raw materials in parts by weight: 20 to 30 parts of radix polygoni multiflori, 8 to 10 parts of prepared rehmannia roots, 10 to 15 parts of arborvitae tops, 10 to 15 parts of rhizoma polygonati, 5 to 8 parts of Chinese wolfberry fruits, 5 to 10 parts of radix angelicae sinensis, 5 to 8 parts of red dates, 8 to 10 parts of spatholobus stems, 5 to 10 parts of glossy privet fruits and 10 to 15 parts of mulberry fruits. The health care tea has the advantages that the natural traditional Chinese medicine raw materials are used; the preparation is simple and convenient; the medicine sources are wide; the cost is low; the effects of warming the kidney to strengthen yang, promoting blood circulation to remove blood stasis and clearing away heat and toxic materials are achieved; the kidney blood flow is improved; the urine protein is reduced; the renal damage is delayed; the recurrence rate is low; the complete reliving rate is high; the medicine property is mild; the absorption of scalp external nutrition can be effectively promoted; the blood circulation is promoted; the hair nutrition state is improved; the hair development speed is high; the effects of nourishing the spleen and the kidneys, nourishing the blood for tranquilization, promoting hair growth, blackening the hair, promoting blood circulation and eliminating toxin are achieved; the materials are made into a beverage; the use is convenient.

The invention provides a traditional Chinese medicine for treating damp heat stagnation type pancreatic cancer and a preparation method thereof. All raw medicinal materials of the traditional Chinese medicine comprise achillea millefolium, herb of sword brake, typhonium divaricatum, Chinese silkvine root-bark, all-grass of matsumura leafflower, setcreasea purpurea, lycopodium serratum, elsholtzia patrini garcke, meadowrue root and rhizome, herb of Japanese farfugium, tushihua, baeckea frutescens, radermachera sinica, silkworm moth, stem and leaf of assam crotalaria and trametes robinioplila. The traditional Chinese medicine provided by the invention can be separately used or can be matched with chemoradiotherapy for use; the traditional Chinese medicine can be used for reducing lumps in a short time, effectively controlling the diffusion and transfer of cancer cells, and enhancing the body immune function to suppress the growth of the cancer cells; meanwhile, no side effects are caused; the aims of enhancing the body immunity while treating and resisting the cancer, relieving pains of patients, stabilizing disease conditions, prolonging the survival period and increasing the proportion of patients realizing clinical complete remission are achieved.

Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38− cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38−ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38− cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.

The invention relates to an authenticating method of a cancer stem cell. Oligonucleotides of pathogenic cancer gene and cancerous cancer gene are marked by biotins to be subjected to in-situ hybridization, and the cell with dual-positive result is identified to be the cancer stem cell. The authenticating method of the cancer stem cell comprises the following step of performing in-situ hybridization on a to-be-detected bone marrow cell smear, wherein the used probe is V-erbB (virus oncogene) and TS gene oligonucleotides marked by digoxin, and the V-erbB oligonucleotide is the oligonucleotide generating mutation / amplification location. The authenticating method can be used as a basis for judging whether the bone marrow of an acute leukemia complete remission (AL-CR) patient is normal or not, so that collection of normal bone marrow is determined and is stored at a low temperature for later use. When leukemia relapse occurs on the AL-CR patient, the normal bone marrow can be used for effective treatment. The other technology in the study, i.e. a V-erbB and TS gene PCR (polymerase chain reaction) gene diagnosis method is combined to detect a specimen, and a negative reaction result supports judgment that whether the bone marrow is normal or not.

The invention belongs to the technical field of medicine, and particularly relates to traditional Chinese medicine for treating advanced pancreatic carcinoma pain. The traditional Chinese medicine for treating the advanced pancreatic carcinoma pain is prepared by the following traditional Chinese herb active ingredients in parts by weight: 3.5 to 4.5 parts of semen hyoscyami, 4 to 6 parts of dark plum, 4 to 6 parts of golden cypress, 2.5 to 3.5 parts of enriched bittern cake, 2.5 to 3.5 parts of borneol, 3.5 to 4.5 parts of sculellaria barbata, 2.5 to 3.5 parts of asarum sieboldii, 3.5 to 4.5 parts of colophony, 4 to 6 parts of frankincense and 4 to 6 parts of myrrh. The traditional Chinese medicine for treating the advanced pancreatic carcinoma pain has the advantages of high complete remission rate, high effectiveness, quick result and less untoward effect.